Last year, BioMedomics was one of the world’s first companies to launch the CE-marked COVID-19 Combined IgM/IgG Rapid Antibody test for qualitative, differential detection of IgM and IgG antibodies to SARS-CoV-2 in human serum, plasma, or whole blood samples in under 15 minutes. The ease of use of the test played a key role in combatting the COVID-19 pandemic and the test is now expected to play a larger role in detecting neutralizing antibodies for assessing the effectiveness of vaccines.
The all new SARS-CoV-2 Antigen Test Kit (LFIA) detects SARS-CoV-2 in nasopharyngeal secretions directly collected from individuals who are suspected of COVID-19 by their healthcare provider. It has a test time of 15 minutes in lower viral presence however in high viral load presence, the positive line can appear as quickly as 3 minutes. The test is easy to use and can be used at the point of care, public locations such as airports, schools and even the neighborhoods and communities in surveillance, contact tracing and initiation of treatment.
The use of SARS-CoV-2 Rapid Antigen Test Kit (LFIA) along with the IgM/IgM Rapid Antibody test offers a complete solution in the diagnosis of COVID-19. For more information, please contact email@example.com or visit https://www.biomedomics.com/products/infectious-disease/sars-cov-2-antigen-test-kit-lfia/.
*Export only. Not for sale in USA.